Tay-Sachs diseaseFrom Wikipedia, the free encyclopedia

(Redirected from Tay Sachs disease)Jump to: navigation, search

'Tay-Sachs disease'Classification & external

resources

ICD-10 E 75.0

ICD-9 330.1

OMIM 272800 272750

DiseasesDB 12916

MedlinePlus 001417

eMedicine ped/3016 

Tay-Sachs disease (abbreviated TSD, also known as "GM2 gangliosidosis") is a genetic disorder, fatal in its most common variant known as Infantile Tay-Sachs disease. TSD is inherited in an autosomal recessive pattern. The disease occurs when harmful quantities of a fatty acid derivative called a ganglioside accumulate in the nerve cells of the brain. Gangliosides are lipids, components of cellular membranes, and the ganglioside GM2, implicated in Tay-Sachs disease, is especially common in the nervous tissue of the brain.

The disease is named after the British ophthalmologist Warren Tay who first described the red spot on the retina of the eye in 1881, and the American neurologist Bernard Sachs who described the cellular changes of Tay-Sachs and noted an increased prevalence in the Eastern European Jewish (Ashkenazi) population in 1887. It has been suggested that asymptomatic carriers of Tay-Sachs (those with one defective version of HEXA and one normal gene) may have a selective advantage, but this has never been proven.

Research in the late 20th century demonstrated that Tay-Sachs disease is caused by mutations on the HEXA gene on chromosome 15. A large number of HEXA mutations have been discovered, and new ones are still being reported. These mutations reach significant frequencies in several populations. French Canadians of southeastern Quebec and Cajuns of southern Louisiana have a carrier frequency similar to Ashkenazi Jews, but they carry a different mutation. Most HEXA mutations are rare, and do not occur in genetically isolated populations. The disease can potentially occur from the inheritance of two unrelated mutations in the HEXA gene, one from each parent.

Contents

[hide] 1 Symptoms 2 Etiology and pathogenesis 3 Testing and prevention 4 Therapy 5 Epidemiology 6 References

7 External links

[edit] Symptoms

Fundus photograph showing retina changes associated with Tay-Sachs disease.

Tay-Sachs is classified in variant forms, based on the time of onset of neurological symptoms.[1] The variant forms reflect diversity in the mutation base.

All patients with Tay-Sachs have a "cherry-red" spot, easily observable by a physician using an ophthalmoscope, in the back of their eyes (the retina). This red spot is the area of the retina which is accentuated because of gangliosides in the surrounding retinal ganglion cells (which are neurons of the central nervous system). The choroidal circulation is showing through "red" in this region of the fovea where all of the retinal ganglion cells are normally pushed aside to increase visual acuity. Thus, the cherry-red spot is the only normal part of the retina seen. Microscopic analysis of neurons shows that they are distended from excess storage of gangliosides.

Infantile TSD. Infants with Tay-Sachs disease appear to develop normally for the first six months of life. Then, as nerve cells become distended with gangliosides, a relentless deterioration of mental and physical abilities occurs. The child becomes blind, deaf, and unable to swallow. Muscles begin to atrophy and paralysis sets in. Death usually occurs before the age of 4 or 5.

Juvenile TSD. Extremely rare, Juvenile Tay-Sachs disease usually presents itself in children between 2 and 10 years of age. They develop cognitive, motor, speech, and swallowing difficulties; unsteadiness of gait (ataxia), and spasticity. Patients with Juvenile TSD usually die between 5-15 years.[2]

Adult/Late Onset TSD. A rare form of the disorder, known as Adult Onset Tay-Sachs disease or Late Onset Tay-Sachs disease (LOTS), occurs in patients in their 20s and early 30s. LOTS is frequently misdiagnosed, and is usually non-fatal. It is characterized by unsteadiness of gait and progressive neurological deterioration. Symptoms of LOTS, which present in adolescence or early adulthood, include speech difficulties (dysarthria), swallowing difficulties (dysphagia), unsteadiness of gait (ataxia), spasticity, cognitive decline, and psychiatric illness, particularly schizophrenic-like psychosis. Patients with LOTS frequently become wheelchair-bound in adulthood, but many live full adult lives if psychiatric and physical difficulties are accommodated. Psychiatric symptoms and seizures can be controlled with medications. [3][4]

[edit] Etiology and pathogenesis

Tay-Sachs disease is inherited in the autosomal recessive pattern, depicted above.

The condition is caused by insufficient activity of an enzyme called hexosaminidase A that catalyzes the biodegradation of fatty acid derivatives known as gangliosides. Hexasaminidase A is a vital hydrolytic enzyme , found in the lysosomes, that breaks down lipids. When Hexasaminidase A is no longer functioning properly, the lipids accumulate in the brain and cause problems. Gangliosides are made and biodegraded rapidly in early life as the brain develops. Patients and carriers of Tay-Sachs disease can be identified by a simple blood test that measures hexosaminidase A activity. TSD is a recessive genetic disorder, meaning that both parents must be carriers in order to give birth to an affected child. Even then, there is only a 25% chance with each pregnancy of having a child with TSD. Prenatal monitoring of pregnancies is available.

Hydrolysis of GM2-ganglioside requires three proteins. Two of them are subunits of hexosaminidase A, and the third is a small glycolipid transport protein, the GM2 activator protein (GM2A), which acts as a substrate specific cofactor for the enzyme. Deficiency in any one of these proteins leads to storage of the ganglioside, primarily in the lysosomes of neuronal cells. Tay-Sachs disease (along with GM2-gangliosidosis and Sandhoff disease) occurs because a genetic mutation inherited from both parents inactivates or inhibits this process. Most Tay-Sachs mutations appear not to affect functional elements of the protein. Instead, they cause incorrect folding or assembly of the enzyme, so that intracellular transport is disabled. [5]

The disease results from mutations on chromosome 15 in the HEXA gene encoding the alpha-subunit of the lysosomal enzyme beta-N-acetylhexosaminidase A. More than 90

mutations have been identified to date in the HEXA gene, and new mutations are still being reported. These mutations have included base pair insertions and deletions, splice site mutations, point mutations, and other more complex patterns. Each of these mutations alter the protein product, and thus inhibit the function of the enzyme in some manner. In recent years, population studies and pedigree analysis have shown how such mutations arise and spread within small founder populations.

For example, a four base pair insertion in exon 11 (1278insTATC) results in an altered reading frame for the HEXA gene. This mutation is the most prevalent mutation in the Ashkenazi Jewish population, and leads to the infantile form of Tay-Sachs disease.[6] The same mutation occurs in the Cajun population of southern Louisiana, an American ethnic group that has been isolated for several hundred years because of linguistic differences. Researchers have speculated that it may have entered this population because a Jewish merchant family assimilated into Cajun society.

An unrelated mutation, a long sequence deletion, occurs with similar frequency in families with French Canadian ancestry, and has the same pathological effects. Like the Ashkenazi Jewish population, the French Canadian population grew rapidly from a small founder group, and remained isolated from surrounding populations because of geographic, cultural, and language barriers. In the early days of Tay-Sachs research, the mutations in these two populations were believed to be identical. Some researchers claimed that a prolific Jewish ancestor must have introduced the mutation into the French Canadian population. This theory became known as the "Jewish Fur Trader Hypothesis" among researchers in population genetics. However, subsequent research has demonstrated that the two mutations are unrelated, and pedigree analysis has traced the French Canadian mutation to a founding family that lived in southern Quebec in the late 17th century.[7]

Tay-Sachs Disease can potentially result from the inheritance of two unrelated mutations in the HEXA gene, one from each parent. Classic infantile TSD results when a child has inherited mutations from both parents that completely inactivate the biodegradation of gangliosides. Late onset forms of the disease occur because of the diverse mutation base. Patients may technically be heterozygotes, but with two different HEXA mutations that both inactivate, alter, or inhibit enzyme activity in some way. When a patient has at least one copy of the HEXA gene that still enables some hexosaminidase A activity, a later onset form of the disease occurs.

[edit] Testing and prevention

Screening for Tay-Sachs disease was one of the first great successes of the emerging field of genetic counseling and diagnosis. Jewish communities, both inside and outside of Israel, embraced the cause of genetic screening from the 1970s on. Success with Tay-Sachs disease lead Israel to become the first country to offer free genetic screening and counseling for all couples. Israel has become a leading center for research on genetic disease. Both the Jewish and Arab/Palestinian populations in Israel contain many ethnic

and religious minority groups, and Israel's initial success with Tay-Sachs disease has lead to the development of screening programs for other diseases.

Genetic screening for carriers of Tay-Sachs disease is possible because an inexpensive enzyme assay test is available. It detects lower levels of the enzyme hexosaminidase A in serum. Developed during the 1970s, the enzyme assay test is not as accurate as genetic testing based on polymerase chain reaction (PCR) techniques, however it is cost effective for much broader use and allows screening for a disease that is rare in most populations. PCR testing is more effective when the ancestry of both parents is known, allowing for proper selection of genetic markers. Genetic counselors, working with couples that plan to conceive a child, assess risk factors based on ancestry to determine which testing methods are appropriate.

Proactive testing has been quite effective in eliminating Tays-Sachs occurrence amongst Ashkenazi Jews. Of the 10 babies born with Tay-Sachs in North America in 2003, none were born to Jewish families. In Israel, only one child was born with Tay-Sachs in 2003, and preliminary results from early 2005 indicated that none were born with the disease in 2004. Three approaches have been used to prevent or reduce the incidence of Tay-Sachs disease in the Ashkenazi Jewish population:

Prenatal diagnosis and selective abortion. If both parents are identified as carriers, prenatal genetic testing can determine whether the fetus has inherited a defective copy of the gene from both parents. For couples who are willing to terminate the pregnancy, this eliminates the risk of Tay-Sachs, but selective abortion raises ethical issues for many families.[8]

Mate selection. In Orthodox Jewish circles, the organization Dor Yeshorim carries out an anonymous screening program so that couples who are likely to conceive a child with Tay-Sachs or another genetic disorder can avoid marriage.[9]

Nomi Stone of Dartmouth College describes this approach. "Orthodox Jewish high school students are given blood tests to determine if they have the Tay-Sachs gene. Instead of receiving direct results as to their carrier status, each person is given a six-digit identification number. Couples can call a hotline, if both are carriers, they will be deemed 'incompatible.' Individuals are not told they are carriers directly to avoid any possibility of stigmatization or discrimination. If the information were released, carriers could potentially become unmarriageable within the community." Anonymous testing eliminates the stigma of carriership while decreasing the rate of homozygosity in this population. Stone notes that this approach, while effective within a confined population such as Hasidic or Orthodox Jews, may not be effective in the general population.[10]

Preimplantation genetic diagnosis . By retrieving the mother's eggs for in vitro fertilization and conceiving a child outside the womb, it is possible to test the embryo prior to implantation. Only healthy embryos are selected for transfer into the mother's womb. In addition to Tay-Sachs disease, PGD has been used to prevent cystic fibrosis, sickle cell anemia, Huntington disease, and other genetic

disorders.[11] However this method is expensive. It requires invasive medical technologies, and is beyond the financial means of many couples.

[edit] Therapy

There is currently no cure or treatment for TSD. Even with the best care, children with Infantile TSD die by the age of 5, and the progress of Late-Onset TSD can only be slowed, not reversed. However, research is ongoing. Several methods of treatment are being investigated, although significant hurdles remain before any of them pass the experimental stages.

Enzyme replacement therapy . The goal would be to replace the missing enzyme, a process similar to insulin injections for diabetes. However, the enzyme has proven to be too large to pass through the blood into the brain through the blood-brain barrier. Blood vessels in the brain develop junctions so small that many toxic (or large) molecules cannot enter into nerve cells and cause damage. Researchers have also tried instilling the enzyme into cerebrospinal fluid, which bathes the brain. However, neurons are unable to take up the large enzyme efficiently even when it is placed next to the cell, so the treatment is still ineffective.

Gene therapy . The most recent option explored by scientists has been gene therapy. If the defective genes were to be replaced throughout the brain, Tay Sachs could theoretically be cured. However, researchers working in this field believe that they are years away from the technology to transport the genes into neurons, which would be as difficult as transporting the enzyme. Currently, most research involving gene therapy involves developing a method of using a viral vector to transfer new DNA into neurons. Another approach to gene therapy, under study at Duke University, uses stem cells from umbilical cord blood in an effort to replace the defective gene. Although the Duke University approach has been effective with Krabbé disease, the researchers have not yet reported any results for Tay-Sachs.

Metabolic therapy. Other highly experimental methods being researched involve manipulating the brain's metabolism of GM2 gangliosides. One experiment has demonstrated that, by using the enzyme sialidase, the genetic defect can be effectively bypassed and GM2 gangliosides can be metabolized so that they become almost inconsequential. If a safe pharmacological treatment can be developed, one that causes the increased expression of lysosomal sialidase in neurons, a new form of therapy, essentially curing the disease, could be on the horizon. Metabolic therapies under investigation for Late-Onset TSD include treatment with the drug OGT 918 (Zavesca).[12]

[edit] Epidemiology

Historically, Eastern European people of Jewish descent (Ashkenazi Jews) have a high incidence of Tay-Sachs and other lipid storage diseases. Documentation of Tay-Sachs in this Jewish population reaches back to 15th century Europe. In the United States, about 1 in 27 to 1 in 30 Ashkenazi Jews is a recessive carrier. French Canadians and the Cajun community of Louisiana have an occurrence similar to the Ashkenazi Jews. Irish Americans have a 1 in 50 chance of a person being a carrier. In the general population, the incidence of carriers (heterozygotes) is about 1 in 300. [13]

A continuing controversy is whether heterozygotes, individuals who are carriers of one copy of the gene but do not actually develop the disease, have some selective advantage. The classic case of heterozygote advantage is sickle cell anemia, and some researchers have argued that there must be some evolutionary benefit to being a heterozygote for Tay-Sachs as well. Four different theories have been proposed to explain the high frequency of Tay-Sachs carriers in the Ashkenazi Jewish population:

Heterozygote advantage with tuberculosis resistance. Being a Tay-Sachs carrier may serve as a form of protection against tuberculosis. TB's prevalence in the European Jewish population was very high, in part because Jews were forced to live in ghettos. However, several statistical studies have demonstrated that grandparents of Tay-Sachs carriers (who are more likely to have been carriers themselves) died proportionally from the same causes as non-carriers.[14]

Heterozygote advantage because of higher intelligence. Another theory (attributed to Gregory Cochran) proposes that Tay-Sachs and the other lipid storage diseases that are prevalent in Ashkenazi Jews may enhance dendrite growth and promote higher intelligence when present in carrier form, thus providing a selective advantage at a time when Ashkenazi Jews were restricted to intellectual occupations.[15] (See Ashkenazi intelligence.)

Reproductive compensation. Parents who lose a child because of disease tend to "compensate" by having additional children to replace them, and this may increase the incidence of autosomal recessive disease.[16]

Founder effect . This hypothesis states that the high incidence of the 1278insTATC mutation is the result of genetic drift, which amplified a high frequency that existed by chance in an early founder population.

Because Tay-Sachs disease was one of the first autosomal recessive genetic disorders for which there was an enzyme assay test (prior to polymerase chain reaction testing methods), it was intensely studied as a model for all such diseases. The researchers of the 1970s often favored theories of heterozygote advantage, but failed to find much evidence for them in human populations. They were also unaware of the diversity of the Tay-Sachs mutation base. In the 1970s, complete genomes had not yet been sequenced, and researchers were unaware of the extent of polymorphism. The contribution to evolution of genetic drift (as opposed to natural selection) was not fully appreciated.

Since the 1970s, DNA sequencing techniques using PCR have been applied to many genetic disorders, and in other human populations. Several broad genetic studies of the Ashkenazi population (not related to genetic disease) have demonstrated that the

Ashkenazi Jews are the descendants of a small founder population, which may have gone through additional population bottlenecks. These studies also correlate well with historical information about Ashkenazi Jews. Thus, a preponderance of the recent studies have supported the founder effects theory.[17][18][19]

[edit] References

1. ̂ National Institute of Neurological Disorders and Stroke. Tay-Sachs Disease Information Page. Retrieved on July 26, 2006.

2. ̂ Moe, MD, Paul G. & Tim A. Benke, MD, PhD (2005). "Neurologic & Muscular Disorders", Current Pediatric Diagnosis & Treatment, 17th. 

3. ̂ Rosebush PI, MacQueen GM, Clarke JT, Callahan JW, Strasberg PM, Mazurek MF. (1995). "Late-onset Tay-Sachs disease presenting as catatonic schizophrenia: diagnostic and treatment issues". Journal of Clinical Psychiatry 56 (8): 347-53. PMID 7635850. 

4. ̂ Neudorfer O, Pastores GM, Zeng BJ, Gianutsos J, Zaroff CM, Kolodny EH (2005). "Late-onset Tay-Sachs disease: phenotypic characterization and genotypic correlations in 21 affected patients". Genetics in Medicine 7 (2): 119-23. PMID 15714079. 

5. ̂ Mahuran DJ (1999). "Biochemical consequences of mutations causing the GM2 gangliosidoses". Biochim Biophys Acta 1455 (2-3): 105-38. PMID 10571007. 

6. ̂ Tel Aviv University, Department of Human Genetics, Bioinformatics Unit. Genedis: Human Genetics Disease Database. Retrieved on July 26, 2006.

7. ̂ Keats, B. J., Elston, R. C., and Andermann, E. (1987). "Pedigree discriminant analysis of two French Canadian Tay-Sachs families.". Genetic Epidemiology 4 (2): 77-85. PMID 2953646. 

8. ̂ Stoller, David (1997). "Prenatal Genetic Screening: The Enigma of Selective Abortion". Journal of Law and Health 12. 

9. ̂ Ekstein, J and Katzenstein, H (2001). "The Dor Yeshorim story: community-based carrier screening for Tay-Sachs disease.". Advances in Genetics 44: 297-310. 

10. ̂ Nomi Stone. Erasing Tay-Sachs Disease. Retrieved on August 16, 2006. 11. ̂ Preimplantation Genetic Diagnosis 12. ̂ Kolodny, E. H.; Neudorfer, O.; Gianutsos, J.; Zaroff, C.; Barnett, N.; Zeng, B.;

Raghavan, S.; Torres, P.; Pastores, G. (2004). "Late-onset Tay-Sachs disease: natural history and treatment with OGT 918 (Zavesca[TM]).". Source Journal of Neurochemistry 90 (54). ISSN 0022-3042. 

13. ̂ Tel Aviv University, Department of Human Genetics, Bioinformatics Unit. Genedis: Human Genetics Disease Database. Retrieved on July 26, 2006.

14. ̂ Spyropoulos B, Moens PB, Davidson J, and Lowden JA. (1981). "Heterozygote advantage in Tay-Sachs carriers?". American Journal of Human Genetics (3): 375-80. 

15. ̂ Gregory Cochran, Jason Hardy, and Henry Harpending. Natural History of Ashkenazi Intelligence. Retrieved on Jan 29, 2006.

16. ̂ Koeslag, JH and Schach, SR (1984). "Tay-Sachs disease and the role of reproductive compensation in the maintenance of ethnic variations in the incidence of autosomal recessive disease". Annals of Human Genetics (3): 275-281. 

17. ̂ Risch, N, Tang, H, Katzenstein, H, Ekstein, J (2003). "Geographic distribution of disease mutations in the Ashkenazi Jewish population supports genetic drift over selection". American Journal of Human Genetics 72 (4): 812-822. 

18. ̂ Frisch A, Colombo R, Michaelovsky E, Karpati M, Goldman B, Peleg L. (2004). "Origin and spread of the 1278insTATC mutation causing Tay-Sachs disease in Ashkenazi Jews: genetic drift as a robust and parsimonious hypothesis.". Human Genetics 114 (4): 366-76. PMID 14727180. 

19. ̂ Slatkin, M (2004). "A population-genetic test of founder effects and implications for Ashkenazi Jewish diseases". American Journal of Human Genetics 75 (2): 282-293. 

[edit] External links

National Tay-Sachs & Allied Diseases Association NINDS Tay-Sachs Disease Information Page tay-sachs.org Tay-Sachs disease , Genetics Home Reference at NLM

v • d • e

Metabolic pathology (E70-90)[hide]

amino-acids Phenylketonuria - Alkaptonuria - Ochronosis - Tyrosinemia - Maple syrup urine disease - Propionic acidemia - Methylmalonic acidemia - Isovaleric acidemia - Primary carnitine deficiency -

Cystinuria - Cystinosis - Hartnup disease - Homocystinuria - Citrullinemia - Hyperammonemia - Glutaric acidemia type 1

carbohydrates Lactose intolerance - Glycogen storage disease (type I, type II, type III, type IV, type V), Fructose intolerance, Galactosemia

Lipid storage disorders Sphingolipidoses: Gangliosidosis - GM2 gangliosidoses (Sandhoff disease, Tay-Sachs disease) - GM1 gangliosidoses - Mucolipidosis type IV - Gaucher's disease - Niemann-

Pick disease - Farber disease - Fabry's disease - Metachromatic leukodystrophy - Krabbe diseaseNeuronal ceroid lipofuscinosis (Batten disease) - Cerebrotendineous xanthomatosis - Wolman disease

- Cholesteryl ester storage diseaseList of fatty acid metabolism disorders - Hyperlipidemia - Hypercholesterolemia - Familial

hypercholesterolemia - Xanthoma - Combined hyperlipidemia - Lecithin cholesterol acyltransferase deficiency - Tangier disease - Abetalipoproteinemia

mineral metabolism Cu Wilson's disease/Menkes disease - Fe Haemochromatosis - Zn Acrodermatitis enteropathica - PO4

3- Hypophosphatemia/Hypophosphatasia - Mg2+

Hypermagnesemia/Hypomagnesemia - Ca2+ Hypercalcaemia/Hypocalcaemia/Disorders of calcium metabolism

fluid, electrolyte and acid-base balance Electrolyte disturbance - Na+ Hypernatremia/Hyponatremia - Acidosis (Metabolic, Respiratory, Lactic) - Alkalosis (Metabolic, Respiratory) - Mixed disorder of

acid-base balance - H2O Dehydration/Hypervolemia - K+ Hypokalemia/Hyperkalemia - Cl-

Hyperchloremia/Hypochloremiaporphyrin and bilirubin Acatalasia - Gilbert's syndrome - Crigler-Najjar syndrome - Dubin-Johnson syndrome - Rotor syndrome - Porphyria (Acute intermittent porphyria, Gunther's disease, Porphyria

cutanea tarda, Erythropoietic protoporphyria, Hepatoerythropoietic porphyria, Hereditary coproporphyria, Variegate porphyria)

glycosaminoglycan Mucopolysaccharidosis - Hurler syndrome - Hunter syndrome - Sanfilippo syndrome - Morquio syndrome

glycoprotein I-cell disease - Pseudo-Hurler polydystrophy - Aspartylglucosaminuria - Fucosidosis - Alpha-mannosidosis - Sialidosis

other Alpha 1-antitrypsin deficiency - Cystic fibrosis - Familial Mediterranean fever - Lesch-Nyhan syndrome

Retrieved from "http://en.wikipedia.org/wiki/Tay-Sachs_disease"

Categories: Genetic disorders | Ashkenazi Jews topics | Neurology

Views

Article Discussion Edit this page History

Personal tools

Sign in / create account

Navigation

Main page Community portal Featured content Current events Recent changes Random article About Wikipedia Contact us Make a donation Help

Search

 

Toolbox

What links here Related changes Upload file Special pages Printable version Permanent link Cite this article

In other languages

Català Deutsch Español Français Italiano 日本語 Polski Slovenčina Suomi

This page was last modified 02:07, 15 March 2007. All text is available under the terms of the GNU Free Documentation License.

(See Copyrights for details.) Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc., a US-registered 501(c)(3) tax-deductible nonprofit charity.

Privacy policy About Wikipedia Disclaimers